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Abstract 
 
Characterization of Sentinel Lymph Nodes Using Molecular Imaging with Dual Targeted 
Microbubbles in a Swine Model 
Kartikeya Puranik  
Flemming Forsberg, PhD and Peter Lewin, PhD 
 
This work examines the characterization of sentinel lymph nodes (SLNs) in a melanoma swine 
model using dual targeted microbubble molecular imaging. Melanoma drainage into the SLNs is 
an important prognostic factor for predicting patient survival. This project proposes the 
identification of SLNs using a reticuloendothelial specific ultrasound contrast agent (UCA) and 
subsequently using a molecular contrast enhanced ultrasound imaging (CEUS) with dual targeted 
microbubbles to characterize metastatic spread (in an animal model). The two specific aims were: 
1) to determine ex vivo binding affinity of dual targeted UCA to metastatic SLNs 2) to use 
molecular CEUS to characterize SLNs using histology and immunohistochemistry as reference 
standards. The potential benefit from this study will be a development of a minimally-invasive 
imaging method using UCAs to precisely localize and characterize SLN’s thereby reducing the 
need to perform lymph node resections in patients.     
  XV
   
 
To test the ex vivo binding of the dual targeted and IgG (control) UCAs three set of 5 metastatic 
and 5 benign nodes where used. Furthermore, to check the microbubble specificity 24 slides were 
antigen blocked. After exposure free floating or unbounded microbubbles were removed with PBS. 
Subsequently, slides were dried and imaged using a microscope in phase contrast and normal 
modes to quantify the microbubble attachment. For the in vivo characterization of SLNs using 
molecular CEUS, 6 swine initially received a peritumoral injection of Sonazoid, (GE Healthcare, 
Oslo, Norway) to identify SLNs. Next, a dual targeted UCA was administered and imaged (after 
a 4 minute delay to allow for attachment). Microbubble retention was compared to that of IgG 
injections.  
In ex-vivo there was a significant difference between the number of dual targeted and IgG 
microbubbles attached in metastatic SLNs (0.06±0.04 vs 0.05±0.03; p=0.001) visualized in phase 
contrast mode. However, in normal mode this relationship was reversed (0.06±0.05 vs 0.09±0.04; 
p=0.03). Since there should be no IgG attachment this indicates that other cell structures may be 
counted as microbubbles. Additionally, images from SLNs with a metastatic involvement >65% 
had a dark background making it difficult to differentiate microbubbles from background. In vivo 
11 SLN and 13 non-SLNs were imaged. Metastatic involvement greater than 5% was detected in 
7 SLNs by pathology. The mean signal intensity of the dual-targeted contrast agent in the 
metastatic SLNs (17.2±15.8) was significantly higher than in the IgG-targeted control LNs 
(1.5±1.3; p = 0.036), while there were no significant differences in benign LNs (1.5±0.8 vs 
1.6±1.6; p=0.87). There was a significant difference in dual-targeted contrast retention in 
metastatic vs. benign LNs (p=0.04). However, IgG-targeted control UCA demonstrated no 
significant retention difference in metastatic vs. benign LNs (p=0.88).  
  XVI
   
 
In conclusion, the ex vivo study encountered unexpected variability limiting the results. On 
the other hand, the in vivo data showed a significant retention of dual targeted microbubble in 
metastatic SLNs when compared to IgG controls, while there was no significance for the benign 
nodes. This suggests that molecular CEUS with a dual targeted UCA can be used to non-invasively 
characterize metastatic SLNs; at least in a melanoma swine model and maybe in the future in 
humans. 
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1. INTRODUCTION 
 
 
1.1 An Overview 
 
Angiogenesis is the growth of new blood vessels from existing blood vessels, and is 
the primary process by which reproduction, wound repair and development takes place. 
Normally, pro-angiogenic and anti-angiogenic factors maintain an equilibrium resulting in 
controlled angiogenesis. Pathological angiogenesis (neovascularization) is when there is 
abnormal, uncontrolled rapid growth of blood vessels. Uncontrolled growth of blood vessels is 
associated with a number of diseases and therefore plays an essential role in growth of tumor and 
development of metastasis [1]. During the angiogenic process, a pathway is created for cancer 
cells to spread through the blood or the lymphatic system [2-4]. Angiogenic process is a complex 
process and involves two phases, initial phase where the growth of tumor takes place and is 
known as the avascular phase; subsequent phase where tumor expansion is initiated and is 
termed as neovascularization or vascular phase. This creates a pathway for the cancer cells to 
spread through the blood and the lymphatic system. 
The onset of angiogenesis leads to the activation, migration and proliferation of the 
endothelial cells which is regulated by specific growth factors, which are secreted directly by the 
tumor or in some cases they activate angiogenic compounds stored within the extra-cellular 
matrix which are regulated by the changes in the cell adhesion molecules. P-selectin is one such 
cell adhesion molecule which covers the inner surface of the blood vessels and activated 
platelets. It plays the fundamental role of tumor metastasis by getting expressed on the surface of 
2 
 
both activated endothelial cells and platelets. This helps the cancer cell to invade in the blood 
stream for metastasis along with multiple growth factors [5-6]. In particular changes in one 
category of adhesion molecules, integrin’s regulate the activation of the angiogenic compounds 
in vascular endothelial growth factor. αVβ3-integrin expression increases in proliferating vascular 
endothelial cells during tumor angiogenesis. Due to their fundamental role in angiogenesis and in 
tumor metastasis these cell adhesion molecules act as a positive regulator of angiogenesis [5-6]. 
Additionally, these molecules activate signaling cascade that regulate gene expression, 
cytoskeletal organization, cell adhesion and cell survival which results in cancer cells being more 
invasive, more migratory, and better able to survive in different microenvironments [1].  Because 
of their role in tumor growth and migration, both P-selectin and αVβ3-integrin are two best-
characterized molecular markers of tumor angiogenesis and both are overexpressed on tumor 
endothelial cells during tumor angiogenesis.  
Pathological angiogenesis (neovascularization) is the underlying factor for conditions 
such as cancer, skin diseases, cardio-vascular diseases etc. [8]. As a result there has been a rising 
interest in monitoring tumor angiogenesis and anti-angiogenetic therapies. Ultrasound proves to 
be a good diagnostic modality since it provide real time scanning capability with no ionizing 
radiation and less expensive when compared to CT and MRI [9]. The application of clinical 
frequency Doppler ultrasound color flow imaging looked promising initially, however it had 
insufficient sensitivity to monitor small changes caused by the anti-angiogenic therapies [10]. 
Vessels smaller than 100 μm were not visualized using Doppler ultrasound color flow imaging 
[11]. Ultrasound contrast agents (UCA) are made up of gas microbubble stabilized by an outer 
shell. They are small (<8 μm) and can circulate freely through the capillaries. Ultrasound 
contrast agents after isonification with ultrasound, generates a very high echogenic response due 
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to the gaseous core of microbubbles which improves the sensitivity and specificity of diagnostic 
ultrasound imaging by increasing contrast to tissue background ratio up to 25dB [12]. 
Targeted contrast enhanced ultrasound (molecular imaging) i.e. the combination of 
ultrasound technology with novel molecularly-targeted ultrasound contrast agents to assess 
biological binding at molecular level. Molecular contrast agents are small (<10μm) sized 
particles targeted to specific molecular markers developed by adding high affinity binding 
ligands to the surface of the microbubble. After intravenous administration, these targeted 
ultrasound contrast agents accumulate at the tissue sites and overexpress specific molecular 
markers, which causes enhancement of ultrasound imaging signal.  
In our study we inject contrast bubbles into the skin to trace the lymphatic fluid 
drainage path towards SLN from a primary tumor. The bubbles can be picked up first by the 
node closest to the tumor referred as sentinel lymph node. Once a specific area (basin) of lymph 
drainage has been characterized, the sentinel lymph node can be removed surgically and tested in 
the pathology laboratory, the idea being that if any melanoma cells reach the local nodal basin, 
they will show up in the sentinel nodes. Once the lymphatic nodes have been characterized, 
targeted microbubbles are administered made up of P-selectin and αVβ3 because of their role in 
tumor angiogenesis and overexpression on the tumor, the microbubbles will bind to these target 
areas which will enhance the ultrasound signal in the microbubble retention site. Thus the 
purpose of this study is to detect the sentinel lymph nodes and to check if they have metastatic 
involvement using dual targeted UCA.  
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1.2 Thesis Objective 
 
The objective of this thesis work is to characterize sentinel lymph nodes that receive 
drainage from a primary cancer using molecular imaging with dual targeted microbubbles in a 
swine animal model. This study is done to improve the detection of metastatic involvement in 
SLNs using a melanoma swine model. To accomplish this goal Sonazoid (GE Healthcare, Oslo 
Norway), was administered peritumorally around the melanoma tumor which helped in the 
identification of the SLNs. Once the SLNs were identified dual targeted contrast agent was 
intravenously administered to determine metastatic SLN and non-metastatic SLN. This was done 
by quantifying the microbubble retention in the SLNs. It was hypothesized that molecular 
imaging with dual targeted contrast agents will allow precise detection and characterization of 
the metastatic SLN in a swine model. 
Specific Aim 1: To determine the in-vitro binding of dual targeted microbubble to tumor 
vasculature in metastatic lymph nodes 
 
Specific Aim 2: The goal of this study is to characterize sentinel lymph node using dual 
targeted molecular contrast enhanced ultrasound imaging 
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2. BACKGROUND AND LITERATURE REVIEW 
 
This chapter will present a background and review of literature related to tumor 
angiogenesis, ultrasound imaging, diagnosis and imaging of melanoma, contrast enhanced 
ultrasound, molecular contrast enhanced ultrasound and double targeted molecular contrast 
enhanced ultrasound.   
 
2.1 Angiogenesis 
A natural process which involves the growth of new capillary blood vessels in the body is 
termed as angiogenesis. It is an important natural process for healing and reproduction and 
occurs during embryogenesis and early post-natal development. In healthy tissues, the body 
controls the angiogenesis by producing a balance of growth and inhibitory factors. Either too 
much or too little angiogenesis results if the balance between the growth and inhibitory factors is 
disturbed. Abnormal blood vessel growth (pathological angiogenesis: neovascularization) is the 
underlying factor for conditions such as cancer, skin diseases, cardio-vascular diseases etc. [13] 
Solid tumor growth consists of two phases, avascular phase (no or less blood vessels) and 
subsequent vascular phase (consists of blood vessels). Angiogenesis is a complex process and is 
caused due to the imbalance in the pro-angiogenic and anti-angiogenic factor which results in the 
release of angiogenic factors which consist of substances (polypeptides, lipids etc.) that help in 
the formation of blood vessels. This helps the solid tumor to transition from an avascular phase 
to a vascular phase. The development of the intrinsic vascular network helps the tumor mass to 
grow indefinitely. Generation of the vascular phase enables the cells to enter the vasculature and 
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to spread to distant sites (metastasis) [14]. In the avascular phase the cells are 1-2 mm in 
diameter. 
The first evidence of the two phases of cancer was postulate by Judah Folkman in 1963 
and he postulated that survival and growth of tumors requires blood vessels and by cutting off 
the blood vessels the cancer growth can be limited. [15]. He also recognized the existence of 
angiogenesis inhibitors that prevent the induction of new blood vessels. [16] As it is now proven 
that angiogenesis plays a crucial role in tumor growth and metastasis of cancer. A lot of focus is 
given on the regulatory mechanism and the clinical implications mostly to treat cancer by using 
anti-angiogenic therapy. Figure 2.1 depicts the basic step involved in tumor angiogenesis and 
role of tumor development.  
 
 
 
   Figure 2.1: Sequence of angiogenic events on the basis of sprout formation A) endothelial cells activated by 
angiogenic stimulus B) endothelial cells secrete proteases to degrade basement membrane and extra-cellular 
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matrix C) capillary sprout formed as a result of directed endothelial cell migration D) grows by means of cell 
mitosis and migration E) new lumen membrane is formed F) new capillary loop formed G) second generation 
capillary formation starts [17] 
 
 
Approximately 500 million patients are afflicted by angiogenesis-dependent diseases in the 
western nation each year. More than $4 billion have been invested in research and development 
of angiogenesis-based medicines, making it one of the most heavily funded areas of medical 
research. [18] 
 
2.2 Ultrasound Imaging 
 
Ultrasound imaging’s main attraction as an imaging modality lies in its non-invasive 
character and ability to distinguish interfaces between soft-tissues. It is used to image almost 
entire range of internal organs in the abdomen. These include the kidney, liver, spleen, pancreas, 
bladder, major blood vessels and the fetus during pregnancy. Ultrasonic studies which do not 
involve image formation are used to allow the dynamics of blood flow in the cardiovascular 
system 
Ultrasonic waves are sound waves associated with frequencies above the audible range 
and generally extend upward from 20 kHz. Ultrasound transmits acoustic waves through the 
body, some of which is reflected back to the transducer due to differences in tissue impedances. 
Reflected waves are used to generate images. Acoustic impedance (z) is defined as the product of 
density of the medium with the velocity of the sound in the same medium.  
 
z = ρ x c,                                           Eq 1 
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Where ρ is the density of the medium (kg/m3) and c is the velocity of sound in medium (m/s). 
The acoustic impedance determines the degree of reflection and refraction at the interface 
between two media and is referred to as reflection coefficient (R). R= 1 denotes 100% reflection, 
while R=0 denotes 100% transmission of the wave. R for a wave for two media is given as:  
                             R=
z2 – z1
𝑧2+𝑧1
                                                                             Eq 2 
 
Today ultrasound is a popular imaging modality because it is portable, uses non-ionizing 
radiation, provides real time imaging and is relatively inexpensive compared to other imaging 
modalities [10]. Approximately there are 75,000 ultrasound machines compared to 5,000 MRI 
machines in the USA [20].  
 
2.3 Ultrasound Contrast Agents  
Ultrasound contrast agent are gas filled microbubbles surrounded by a shell usually 1-4 
μm in size. After insonification with ultrasound the gaseous core of microbubble causes a very 
high echogenic response due to the gaseous core of microbubbles which improves the sensitivity 
and specificity of diagnostic ultrasound imaging by increasing contrast to tissue background ratio 
up to 25dB [21].  Different type of contrast microbubbles have been synthesized by combining 
different shell compositions such as albumin, galactose, lipids, or polymers with different 
gaseous core such as air, or high molecular weight gases (perfluorocarbon, sulfur hexafluoride, 
or nitrogen) [22].  Due to their small size (1-10 μm) they can mimic the red blood cells and enter 
the capillary network [23]. Due to their small size (1-10 μm) ultrasound contrast agents can be 
administered intravenously and provides an impedance mismatch between the blood and the gas 
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in the microbubble, which enhances the ultrasound contrast by more than 20 dB [24.].  Gramiak 
and Shah in 1968 first discovered contrast agents and proved that the improved reflectivity in the 
blood was due to gas bubbles [25-26]. 
Some of the commercially available contrast agents are listed in the table 2.1. The amount of gas 
in a bolus injection is of the order 20-100 μl [27] 
Table 2.1: Commercially available ultrasound contrast agent. Reproduced from [28]  
Name Manufacturer Year Gas Coating Availability 
Echovist Bayer Schering Pharma 
AG 
1991 Air Galactose Off market 
Albunex Molecular Biosystems 1994 Air Human Albumin Off market 
Levovist Bayer Schering Pharma 
AG 
1996 Air Galactose Off market 
Optison GE Healthcare 1997 C3F8 Human Albumin EU,USA 
Definity Lantheus Medical Imaging 2001 C3F8 Phospholipids Worldwide 
SonoVue Bracco SpA 
 
 
2001 SF6 Phospholipids USA, Europe, 
South Korea, 
China, India, 
Hong Kong, 
Singapore 
Imagent Alliance Pharmaceutical 
Corp. 
2002 C6F14 Phospholipids Off market 
Sonazoid GE Healthcare 2006 C4F10 Phospholipids Japan, South 
Korea, Norway, 
China 
 
 An air bubble has  a fragile, flexible boundry surrounded by fluid (water or blood). 
Following isonification, the bubble undergoes alternate phases of compression and rarefaction 
according to the compression and rarefraction half cycles of the sound wave (as shown in figure 
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2.2). During positive half cycle the size of the bubble reduces, while it expands in the negative 
half cycle. Since, the expansion and compression of the microbubble in the negative and positive 
half cycles are not equal, this results in asymmetrical and non-linear bubble oscillation. [29] 
    
 
 
 
Fig 2.2:Symmetrical Pacing of bubble expansion and compression  during compressional and 
rarefractional half cycles of ultrasound [30] 
 
 
2.4 Contrast Enhanced Ultrasound  
 
Microbubbles have a non-linear response which is used to enhance the contrast relative to 
the surrounding tissue. Some of the imaging methods that can be used to attain this response are 
described here. 
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2.4.1 Harmonic imaging 
 
Ultrasound waves are transmitted at a fundamental frequency f0 and backscattered 
echoes are received from the second harmonic component 2f0 for creating an image (filters are 
used to remove the fundamental component from the waves). This results in the restriction of the 
bandwidth which are available for imaging, to ensure that the fundamental frequencies are 
separated from the received harmonic signal. If the bandwidth of the fundamental signal and the 
2nd harmonic overlap, they can’t be completely separated in the reception process. It is necessary 
to lower the frequency of the transmitted pulse so that both the harmonic frequencies can be 
accommodated within the frequency range of the transducer. Thus, a transducer with a frequency 
[1.5 MHz-4.5 MHz] will be able to transmit a 2 MHz pulse and still have a sufficient bandwidth 
to receive second harmonic spectrum of echoes centered at 4 MHz [31]. One disadvantage of 
harmonic imaging is that the depth of imaging is reduced due to high attenuation of the harmonic 
frequencies when compared to the fundamental frequency [32]. 
 
 
2.4.2     Pulse Inversion Imaging 
  
Patrick Phillips proposed pulse inversion imaging. In this technique two RF pulses are 
fired successively. The pulses fired are inverted in phase with respect to the other. That is in any 
linear system the response of the second pulse is an inverted copy of the response from the first 
pulse and hence the net response of the two pulses is zero. While in a nonlinear system (system 
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with gas microbubbles) the response will not be an inverted copy and the net sum will be non-
zero. The advantage of using pulse inversion method over the filter method of harmonic 
detection is that the overlay between the fundamental and second harmonic is not taken into 
account, and hence transmission spectrum needs not to be restricted [33].  
 
 
2.5 Melanoma cancer  
Melanoma is a malignancy of pigment cell producing cells (melanocytes) which are 
located predominantly in the skin, but can also be found in ears, eyes, GI tract, leptomeninges, 
and oral and genital mucous membranes. Melanoma cancer is commonly known as the skin 
cancer. The figure 2.3 describes the skin layers: epidermis, dermis and subcutis. The top layer of 
the skin is the epidermis and its thickness varies in different types of skin. It is thinnest on the 
eyelids at 0.05mm and thickest on palms and soles at 1.5mm. It consist of the following types of 
cells: 
a) Squamous cells: flat cells found on the external side of skin. Shed once new 
are formed  
b) Basal cells: present in the lower part of the epidermis, called basal layer. 
These cells divide to form new squamous cells  
c) Melanocytes: Cells that can become melanoma. They make a brownish 
substance called as melanin. Melanin protects the deeper layers from the sun 
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Figure 2.3.  Anatomy of the human skin [34]. 
 
Dermis is the middle layer of the skin and contains hair follicles, sweat glands, blood 
vessel and provides the skin its elasticity. Subcutis is the lower most part of the skin and consist 
of fats and collagen cells and protects the body from heat and acts as a shock absorbent.  
  Melanoma is a cancer which starts in the melanocytes. Exposure to ultraviolet 
rays is the major cause of melanomas. Melanoma accounts for only 4% of all skin cancers; 
however it causes the greatest number of skin-cancer related deaths worldwide. 
In last 30 years the incidence of melanoma has tripled in white population in last 30 years. 
Approximately 73,870 Americans (42,670 and 31,200 women) will develop invasive cutaneous 
melanoma in 2015 [35]. Melanoma instances have increased worldwide, highest in Australia and 
New Zealand. According to a most recent analysis of global cancer statistics for melanoma, since 
2012 an age standardization incidence of 34.9 cases per 100,000 men and women in Australia 
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and 35.84 cases per 100,000 men and women in New Zealand, compared to 14.3 cases per 
100,000 men and women in USA were reported [36]. Classification of melanoma stages 
determine the degree to which the melanoma has spread. Early melanoma are localized meaning 
that they are non-invasive and have not penetrated the surface of the skin. Once the melanoma 
has progressed beyond the original site, it is most likely to have reached the lymph nodes that are 
closest to the tumor [37]. The diagnosis of melanoma can be done by lymphatic mapping 
techniques. In this method the drainage pattern of the lymph fluid is determined. In our study we 
inject contrast bubbles into the skin to trace the lymphatic fluid drainage path. The bubbles can 
be picked up first by the node closest to the tumor referred as sentinel lymph node. Once a 
specific area (basin) of lymph drainage has been characterized, the sentinel lymph node can be 
removed surgically and tested in the pathology laboratory, the idea being that if any melanoma 
cells reach the local nodal basin, they will show up in the sentinel nodes. 
 
2.6 Targeted Ultrasound Contrast Imaging   
  Targeted contrast enhanced ultrasound (molecular imaging) i.e. the combination 
of ultrasound technology with novel molecularly-targeted ultrasound contrast agents to assess 
biological binding at molecular level. Molecular contrast agents are small (<10μm) sized 
particles targeted to specific molecular markers developed by adding high affinity binding 
ligands to the surface of the microbubble. After intravenous administration, these targeted 
ultrasound contrast agents accumulate at the tissue sites and overexpress specific molecular 
markers, which causes enhancement of ultrasound imaging signal. 
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 Targeting of the contrast microbubble to a cellular or a molecular surface can be of two 
types; passive or active. Passive targeting refers to the non-specific accumulation of the 
microbubbles at the target site. In the studies by Lindner it has been shown that activated 
leukocytes engulf and absorb microbubbles that are made up of albumin or lipid shell [38]. In 
this study passive targeting was achieved by making the microbubbles negative by introducing 
phosphatidylserine into the shell of the microbubble. Furthermore, these microbubbles were used 
to image the inflamed venules of mouse cremaster muscle [38] Ultrasound images generated 
after the microbubble infusion showed increased contrast enhancement due to the retention and 
accumulation of the phagocytosed and adherent microbubble at the inflammation site [39]. 
In active targeting contrast agent shell is modified which allows selective binding to 
cellular epitopes or other receptors of interest. For non-covalent attachment of biotinylated 
ligands onto the shell of ultrasound microbubble, avidin or streptavidin is commonly used due to 
its wide availability, high effective dissociation constant Kd of 10
-15 molar, and its uses in pre-
clinical experiments [40]. The advantage of using streptavidin/avidin is that it allows binding of 
any biotinylated ligand onto the microbubble surface without designing any new microbubble for 
the vascular target. The disadvantage of using streptavidin is that it can cause immunogenic and 
allergic reactions [41-42]. Another disadvantage is the binding of streptavidin to physiological 
biotin available in human body; needed for synthesis of fatty acids and for gluconeogenesis [43]. 
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Fig 2.4: a) small hydrophilic ligand can be covalently attached to the distal end of the 
carrier lipopolymer b) large protein ligand can be attached by biotin (red) and avidin 
(yellow) links. (60kDa) large size and multiple binding packet create a scaffold, 
supported by polymeric brush (2-5kDa). [44] 
   
2.7 Contrast Enhanced Ultrasound Imaging Technique 
 
 Current clinical ultrasound systems with contrast ultrasound imaging modes use multi-
pulse techniques for non-linear contrast agent detection. Table 2.2 shows current clinical 
ultrasound systems and their respective contrast imaging technologies. 
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Table 2.2: Current clinical ultrasound systems and their respective contrast imaging 
technologies [45]. 
Manufacturer System Technology 
Philips iU22 Pulse Inversion(PI) 
Power Modulation(PM) 
PM/PI 
Coded Contrast Harmonics(CCH) 
General Electric Logiq 9 Coded Harmonic  
Siemens  Sequoia Cadence Contrast Pulse Sequencing 
(CPS) 
Hitachi HI Vision 900 Dynamic Contrast Harmonic 
Imaging (dCHI) 
Wideband Pulse Inversion(PI) 
Toshiba Aplio XG Pulse Subtraction 
Aloka Prosound Alpha 7 Contrast Harmonic Echo using 
ePureHD  
(extended pure harmonic detection ) 
Esaote MyLab GOLD CnTI(Contrast Tuned Imaging) 
 
 
 Multi pulse techniques depend on detection of non-linear imaging signal by modulation 
of either phase or amplitude between successive ultrasound pulses. Microbubble oscillation is 
non-linear, cancelling the receiving echoes will result in a residual signal difference which can 
be used to detect the microbubbles and cancel signal from the surrounding tissue. Signal filtering 
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is not frequency based, still overlapping linear and non-linear signal can be extracted in a 
frequency, by avoiding the bandwidth restriction imposed by harmonic imagining. Additionally, 
broadband imaging pulses can be used to improve axial imaging resolution. This is useful if 
detecting nonlinear signals from microbubbles at the frequency of insonation, which is not 
detected using harmonic imaging as linear and non-linear components will overlap at the 
fundamental frequency [46]. Furthermore, multi-pulse implementation have an additional 
advantage of signal averaging which reduces the noise in the image because two or more pulses 
are used to form an image. 
 
2.8 Molecular Ultrasound Imaging in tumor angiogenesis  
In tumor angiogenesis new blood vessels are formed from the host surrounding 
tissues. Due to this process various molecular markers are overexpressed on the tumor vascular 
endothelial cells [47]. Microbubbles targeted to angiogenesis markers such as vascular 
endothelial growth factor receptor type 2 (VEGFR2), αvβ3 integrin, P-selectin are used to image 
tumor angiogenesis using molecular ultrasound imaging. Positive correlation between in vivo 
ultrasound imaging signal and VEGFR2 expression on tumor endothelial cells of subcutaneous 
breast cancer tumor is demonstrated in the study by Lee [48]. It can be inferred from this study 
that multi-targeting of contrast microbubbles can improve detection of tumor angiogenesis and 
can be used in early detection of cancer using different markers expressed at different time points 
during cancer development.  
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3. MATERIALS AND METHODS 
 
Six Sinclair swine with naturally occurring melanoma (3-7 kg; Sinclair Bio-Resources, 
Columbia, MO) were studied with molecular CEUS, because they have naturally occurring 
melanoma in them.  Further, 70% of these metastases drain into the regional lymph node [49], 
and these swines can have more than one melanoma tumor present at a time. The tumor found in 
these swine’s have the same clinical appearance and histopathology to human melanoma tumors. 
Since the occurrence of melanoma in these swine is high the tumor often (70%) metastasize to 
the regional lymph nodes due to which this animal model is used to characterize lymphatic nodes 
using targeted contrast agents.  
Characterization of SLN for this study is done using two methods: 1) ex-vivo study to 
validate microbubble attachment in the melanoma tissue and 2) clinical study to test the 
attachment of dual targeted contrast agent retention in lymphatic nodes. For the microbubble 
attachment study three methods to test the specificity was done by looking into the number of 
dual targeted microbubble attached, IgG (Control) attachment and the expression of targeted or 
control microbubble on antigen retrieved slides. These tests where hypothesized to check the in-
vitro binding of the microbubbles in swine tissues.   
To characterize the tumor in this animal model Sonazoid (GE Healthcare, Oslo Norway) 
which is a lipid stabilized suspension of perfluorobutane microbubble (mean diameter 2.4-3.5 
μm) was used. Sonazoid was used for the identification of SLNs in swine because of its 
reticuloendothelial system specific properties, which helps in the detection of the SLN with a 
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90% accuracy [46].  For the identification of the tumor Sonazoid was administered around the 
tumor (0.25 ml) in the tumor bearing swine [49]. Sonazoid was administered via peritumoral 
injection around a tumor as it drains into the lymphatic channel and the drainage from the 
primary tumor into the first node in the regional basin can be mapped as done in the earlier 
studies [46].  S3000 scanner (Siemens Medical Solutions, Mountain View, CA) with a 9L4 probe 
was used to identify SLN’s in the swine. The melanoma tumors are present under the skin (2-3 
cm) on the subcutaneous layer of the skin. These tumors are not deeply located so as to scan the 
superficial tumor linear array transducer with frequency range of 9-4 MHz was used since they 
offer ultrasound penetration of 4-5 cm below the skin. Linear array probes were used in the 
earlier studies to accurately identify SLNs in swine melanoma models [46].  
 For the characterization of SLN having metastatic involvement, ultrasound contrast agents 
targeted to specific molecular markers by adding high affinity binding ligands onto the surface of 
contrast agent were created [35, 45]. During angiogenesis there are specific molecular markers 
expressed including vascular endothelial growth factor 2 (VEGFR-2), αVβ3-integrin and p-
selectin [35]. Hence to create an appropriate targeted UCA, a total of 12 abnormal lymph node 
were resected and were submitted for histological examination. The nodes were cut into 5.0µm 
sections and marker expression of the metastatic melanoma within the lymph node vasculature 
was required. To get an idea of the molecular expression the slides containing melanoma where 
stained for VEGFR-2, αVβ3-integrin and p-selectin. Histopathological analysis of the expression 
showed that αVβ3-integrin and p-selectin intensities where 10% higher than VEGFR-2. Hence a 
dual targeted UCA was used for this study. There have been previous studies showing that 
Targestar-SA was used as a targeting ultrasound agent to improve localization of tumor 
vasculature [55], hence Targestar-SA was used in this study as a targeting UCA. Dual targeted 
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UCA was custom manufactured by (Targeson, San Diego, CA), where Targestar, SA 
microbubble were attached with P-selectin and αVβ3-integrin antibodies to the outer microbubble 
shell to create dual-targeted agent. Double targeted microbubble was used because P-selectin and 
αVβ3-integrin are overexpressed during tumor angiogenesis and this would improve microbubble 
attachment to the tumor vasculature [51]. αvβ3-integrin (Millipore Corp, Billerica MA) and P-
Selectin (LifeSpan Biosciences Inc., Seattle WA) were biotinylated using a sulfo NHS-biotin 
linkage kit (Thermo Scientific, Rockford IL). Dual targeted bubbles were fabricated by 
incubating the streptavidin coated Targestar SA (1ml) microbubbles with 25 μl of both αvβ3-
integrin and P-Selectin (biotinylated antibody). This dosage was provided by the technical data 
specification by Targeson. For the control or non-targeted microbubble were fabricated using the 
streptavidin coated microbubble with biotinylated 50 μl of immunoglobulin in 1 ml of Targestar.  
Initially the location of the tumor and subsequent SLN was identified using Sonazoid, 
because of the Sonazoid’s reticuloendothelial specific UCA properties which helps in the 
identification of the melanoma drainage from the primary tumor into the regionals basin’s first 
lymph node defined as the Sentinel Lymph Node. Sonazoid was destroyed for an hour using 
color doppler imaging mode with a mechanical index of MI>0.5, this was also done to detect the 
presence of the contrast agent in the lymphatic channel and the SLN as an acoustic emission 
display. In other words the contrast agent microbubble rupture was depicted as a transient color 
signal [46] destroying the retained Sonazoid in the SLN’s before the dual targeted microbubbles 
were administered into the swine. Dual targeted microbubble injection of (0.25 ml) was 
administered in the swine intravenously and the targeted microbubbles were allowed to circulate 
and bind to the tumor sites for 4 minutes [35]. CEUS scans were performed to characterize 
metastatic SLNs and non-metastatic SLNs. Once the sentinel lymph node was characterized a 
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destruction pulse (high power 100% power optimized) was administered after which a 9 second 
of scans were stored to create a post destruction set. After that, 0.25 ml of non-targeted UCA was 
administered in a random order amount of contrast retained was quantified. The difference in the 
video intensity of the SLN between the pre- destruction and post-destruction was calculated 
which helped calculating the measure of retention of targeted and non-targeted contrast agent in 
the lymphatic node. 
A 4 minute circulation time was allowed for the binding of the targeted microbubble and 
washing out of the unattached free circulating microbubble [35]. Subsequently, metastatic SLNs 
and non- metastatic SLNs were identified on the basis of the retained targeted UCA in the node. 
Approximately, 100 images were acquired from each lymph node after which a high power 
ultrasound destruction sequence of 100% power was applied and another 100 images were 
acquired. The amount of targeted and control bubble retention was compared using t-test, where 
dual targeted microbubble retention was measured in metastatic and benign nodes. And similarly 
the IgG (control) microbubble retention was compared for metastatic vs benign nodes. Post 
ultrasound study the lymph nodes were resected and were submitted to the pathology which was 
used as a reference standard for the detection of metastatic involvement in the nodes.  
 To check the binding affinity of the dual targeted microbubble on the metastatic tissue 
and benign tissue in-vivo bubble attachment studies were performed. 
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3.1.1 Animal Model  
 A total of 6 Sinclair swine (Sinclair Bio-resources, Columbia, MO) with naturally 
occurring melanoma tumors were studied in these experiments. Sinclair swine were selected for 
this experiment because, they have naturally occurring melanoma in them. 70% of these 
metastatic tumors drain into the regional lymph node because of which this animal model was 
selected for this study [52].  Additionally, this swine melanoma resembles in clinical appearance 
and histopathological characteristics to that of a human melanoma tumor. The weight of the 
swine ranged from 3.0 to 7.0 kg   
The swine were pre-medicated using an intramuscular administration of atropine (Med-Pharmex 
Inc., Pomona, CA), 0.04 mg/kg along with telazol (Tiletamine/Zolazepam; Pfizer, New York, 
NY), general anesthesia (3-5 mg/kg) was maintained by isoflurane through an endotracheal tube 
which was 2% to 4%, titrated to have an effect on the entire body [49]. To maintain the body 
temperature within the normal range the swine was placed on a warming blanket. All 
experiments were conducted after Institutional Animal Care and Use Committee approval as per 
the guidelines of the National Institutes of Health and under the supervision from Laboratory 
Animal Services Department. Also, the swine were pre-treated using an intramuscular 
administration of a Toradol (Genentech, Inc., San Francisco, CA) [non-steroidal anti-
inflammatory intravenous injection] 20 mins prior to the injection of the bubbles to characterize 
the lymphatic nodes. This was monitored so as to dilate the blood vessels of the swine for the 
easy passage of the contrast agent and to decrease any possibility of hypertension in the swine. 
[49].   
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3.1.2 Contrast Agents 
 Sonazoid [GE Healthcare, Oslo Norway] a lipid stabilized suspension of perfluororbutane 
microbubble and has a median diameter of 2.4μm -3.5μm, Peritumoral injection of Sonzaoid 
around the tumor was used for the identification of the sentinel lymph node in the tumor swine 
model. [53].For the identification of the drainage of melanoma from primary tumor into the 
regional node and in the SLN was done by suing Sonazoid which was administered 
percutaneously (0.25 ml) in the tumor bearing swine [50]. Peritumoral injection of Sonazoid was 
administered because of its reticuloendothelial property which helps in the identification of the 
SLN in the swine and CEUS was performed using a S3000 scanner (Siemens Medical Solutions, 
Mountain View, CA) with a 9L4 probe was used to identify SLN’s in the swine. A linear array 
transducer probe was used because the tumor and the SLNs are located superficially and linear 
array probe can be used to detect tissues 4-5 cm below the skin. Table 2.3 shows three types and 
properties of the injections used for this study. 
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Table 2.3: Table shows the contrast agents used for this study. There were three types of contrast agents used 
for this study; Sonazoid, Targestar-SA (Dual targeted, biotinylated with antibodies), Targestar-SA (Control, 
biotinylated with immunoglobulin) 
 
 
 
 There are three UCA’s that are approved by the FDA; 1) Optison (GE Healthcare) 2) 
Definity (Lantheus Medical Imaging) 3) Lumason (Bracco Diagnostics).  Double targeted UCA 
was custom manufactured by (Targeson, San Diego, CA), where their ultrasound contrast agent 
Targestar, SA microbubble was attached with P-selectin and αVβ3-integrin antibodies to the outer 
microbubble shell to create dual-targeted agent. Double targeted microbubble was used because 
P-selectin and αVβ3-integrin are overexpressed during tumor angiogenesis and this would 
improve microbubble attachment to the tumor vasculature [51]. αvβ3-integrin (Millipore Corp, 
Billerica MA) and P-Selectin (LifeSpan Biosciences Inc., Seattle WA) were biotinylated using a 
sulfo NHS-biotin linkage kit (Thermo Scientific, Rockford IL). Dual targeted bubbles were 
fabricated by incubating the streptavidin coated Targestar SA microbubbles with 25 μl of both 
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αvβ3-integrin and P-Selectin (biotinylated antibody). For the control or non-targeted microbubble 
were fabricated using the streptavidin coated microbubble with biotinylated 50 μl of 
immunoglobulin in 1 ml of Targestar.  
Initially the location of the enhanced tumor and subsequent SLN is characterized using 
Sonazoid enhanced ultrasound. After an hour interval, during which high mechanical index (MI 
>0.5) ultrasound pulses were applied to destroy any retained Sonazoid in the SLN’s.  After that, 
0.25 ml of non-targeted UCA was administered in a random order and a 30 minute interval was 
maintained before injecting double targeted UCA (0.25ml). Following which molecular CEUS 
was performed and the amount of contrast retained was quantified. The difference in the video 
intensity of the SLN between the pre- destruction and post-destruction was calculated which 
helped calculating the measure of retention of targeted and non-targeted contrast agent in the 
lymphatic node. 
A 4 minute circulation time was allowed for the binding of the targeted microbubble and 
washing out of the unattached free circulating microbubble. Subsequently, SLN area and non-
SLN areas were scanned and lymph node with retained targeted UCA was identified. 
Approximately, 100 images were acquired from each lymph node after which a high power 
ultrasound destruction sequence was applied and another 100 images were acquired. The amount 
of targeted and control bubble retention was compared using t-test on groups of benign and 
metastatic sentinel lymph node (determined by the histological analysis)  
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3.1.3 Imaging Equipment  
A commercially available ultrasound scanner S3000 (Siemens Medical Solutions, Mountain 
View, CA) with a high frequency broad bandwidth linear array 9L4 probe was used to perform 
conventional and CEUS scanning. The acoustic power was kept low so as to minimize the 
Sonazoid destruction (MI< 0.2). This scanner was used because of the availability of the contrast 
imaging packages such as the CPS mode. CadenceTM Pulse Sequencing (Siemens) was used to 
acquire CEUS data. It is a technique were low-power multi-pulse are used where three pulses 
with varied phase and amplitude are transmitted and the resulting echoes are summed. CPS 
imaging results in considerable tissue suppression, allowing for better detection of the contrast 
microbubbles. CPS should be used at low mechanical index in order to prevent bubble 
destruction [54]. 
Initially the location of the enhanced tumor and subsequent SLN is characterized using 
Sonazoid enhanced ultrasound. After an hour interval, during which high mechanical index (MI 
>0.5) ultrasound pulses were applied to destroy any retained Sonazoid in the SLN’s.  
Subsequently, 0.25 ml of non-targeted UCA was administered in a random order and a 30 minute 
interval was maintained before injecting double targeted UCA (0.25ml). Following which 
molecular CEUS was performed and the amount of contrast retained was quantified. The 
difference in the video intensity of the SLN between the pre- destruction and post-destruction 
was calculated which helped calculating the measure of retention of targeted and non-targeted 
contrast agent in the lymphatic node. 
A 4 minute circulation time was allowed for the binding of the targeted microbubble and 
washing out of the unattached free circulating microbubble [59]. Subsequently, SLN area and 
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non-SLN areas were scanned and lymph node with retained targeted UCA was identified. 
Approximately, 100 images were acquired from each lymph node after which a high power 
ultrasound destruction sequence was applied and another 100 images were acquired [58]. The 
amount of targeted and control bubble retention was compared using t-test on groups of benign 
and metastatic sentinel lymph node (determined by the histological analysis)  
For the pathological analysis of the tumor specimens, a semi- automated histomorphometry was 
used which is based on a Micropublisher 5.0 RTV color CCD camera (Qimaging, Surrey, 
Canada) attached to a Labophot-2 microscope (Nikon, Melville, NJ). ImagePro Plus software 
(Media Cybernetics, Silver Spring, MD) was used to write a subroutine to perform image 
analysis and additionally to control and operate the motorized stage setup which is attached to 
the microscope. ImagePro Plus software was used to quantify the number of microbubbles 
attached on a tissue. Attached microbubble were quantified on metastatic node vs benign node. 
  
3.1.4 Acquisition of the Ultrasound data  
 Conventional grayscale Ultrasound examinations of the SLN’s and LC’s was performed 
using the S3000 scanner with a high frequency linear array (9L4). These methods have been 
established in the earlier studies [56-57].  For the identification of the lymphatic nodes and the 
size, location of the tumor vasculature, ultrasound scans are performed using gray scale and CPS 
mode. CPS mode was used to detect the retention of dual targeted microbubbles in the sentinel 
lymph node. 0.25 ml of peritumoral injection of Sonazoid is administered around the melanoma 
tumor close proximity of the primary tumor at 12, 3, 6 and 9-o’ clock positon (four injections of 
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0.25ml each) this process has been established by our group’s previous study on detection of 
SLN and non-SLN melanomas [46].  
Sonazoid was used because it helps in the identification of the sentinel lymph node, it is a 
reticuloendothelial tissue-specific ultrasound agent. And it has been shown that the ability to 
detect the lymphatic channel using this UCA is 90% [46].  After the identification of SLNs by 
Sonazoid microbubbles they are destroyed with a high mechanical index wave with 100% power, 
this was done using a power doppler scans [46]. After an hour of Sonazoid destruction dual 
targeted injection were administered intravenously to characterize metastatic SLNs. 4 minutes 
are allowed for the targeted microbubble to circulate and bind to the metastatic lymph nodes 
[35]. Subsequently, the nodes were scanned and to check the microbubble retention a high 
mechanical index wave is initiated called the destruction pulse [45]. The destruction pulse 
destroys all the microbubble at a specific location. Once the destruction pulse is stopped free 
circulating microbubble fill the node again. Ultrasound scan post destruction pulse are stored for 
9 seconds and further ultrasound scans for pre destruction pulse and post destruction pulse were 
saved for offline analysis.  
3.1.5 Approach for Image Processing 
 For the purpose of image processing two data sets were used; pre-destruction data set and 
post-destruction data set so as to get the amount of microbubble retention in a lymph node. These 
data sets are a series of sequential frames of images composed as a cine clip. Since the tumor 
location is on the epidermis there is negligible motion artifacts in the scan.  Every frame in the 
pre destruction set was averaged to give a resultant averaged image, similarly a post destruction 
image was created. To measure the amount of retained molecule in a SLN, pre destruction pulse 
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set was subtracted from the post-destruction set. The resultant gives the amount of retained 
microbubbles in the SLN. Since the images are in RGB, they were converted into HSI using 
ImageJ Software. The intensity component of the scan was used to quantify the results.   
  3.1.5.1 Cine loop for pre-destruction set 
  The cine loop of pre destruction data set is of n images acquired after 4 minutes of 
intravenous administration of the microbubble and took a total of 100 frames. The 4 minute time 
was allowed for the microbubble to float in the tumor vasculature and allow it to get attached to 
the overexpressed markers αvβ3-integrin and P-Selectin on the endothelium of the tumor vessel. 
The video intensity consist of the following components; a) intensity from free circulating 
nonattached microbubble b) intensity from the attached microbubble to the endothelial cells [58] 
 
3.1.5.2 Cine loop for post-destruction set 
    For the post destruction reference data set a set of n-images acquired after destruction of 
the targeted microbubbles; the microbubbles destroyed in real time by applying a high power 
pulse through a transducer. At a rate of 20 Hz, 100 frames were taken for a time duration of 9 
seconds were taken for the study. After the destruction of the microbubble and re-filling of the 
tumor vessel with freely circulating microbubble, the video intensity consist of the following; 
video intensity from free and circulating microbubble [59]. 
3.1.5.3 Pairing and subtraction of the data set 
Initially the images were paired from both pre and post destruction and their difference is 
calculated which shows the retention of microbubble in a tumor vasculature [56-58]. It can be 
31 
 
inferred from the resultant image that if there was some microbubble retention seen, it means that 
the node had metastatic involvement in it [59]. This helps in the detection of metastatic SLN’s in 
the swine model.  
 
3.1.6 Analysis of the Ultrasound data  
In order to study the ultrasound data for the bubbles attached and free floating in the 
tumor vasculature the imaging frames were recorded digitally and analyzed offline with the 
commercial available software ImageJ (NIH, Bethesda, MD). Two sets of cine clips before and 
after a high-power destruction sequence (100% power) were acquired, this was done to quantify 
the microbubble attached to the tumor vasculature [57-59]. The average video intensity pre- to 
post-destruction was measured as to depict the targeted contrast retention in the LNs. For the 
analysis of the images, average mean intensity of the pre-destruction images were subtracted 
with the average mean intensity post- destruction images [58-59]. To check the attachment of 
targeted microbubble in metastatic SLN and benign nodes were scanned using CEUS [57-56]. 
Based on which a  comparison was done to see the retention of dual targeted contrast agent over 
malignant to benign nodes and similarly the same procedure was used for IgG targeted control.  
After the administration of dual targeted microbubble a 4 minute break was scheduled so 
as to allow the dual targeted contrast agent to bind to the specific tumor vasculature [59]. After 
the break time the attached microbubble were scanned to check metastatic involvement of a node 
[58]. Once the microbubbles were identified in the lymph node the pre-destruction scans were 
saved to be analyzed offline. Destruction pulse was administered over the lymph node; 
destruction pulse is a high mechanical index ultrasound pulse which destroys all the microbubble 
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in that region [59]. Following the destruction pulse, a reperfusion of free-circulating microbubble 
was seen in the SLNs. A 9 second video frame scan was saved for offline analysis for the post 
destruction sequence. For the calculation of mean intensity of the microbubbles attached the 
following equation is used: 
    Microbubble Retention= Averaged pre-destruction scans – Averaged post-destruction scans 
[58]   
Averaging of 9 seconds of frames of the pre-destruction sequence was performed for dual 
targeted injection. The figure 3.1 shows the pre destruction averaged image where the CEUS 
signal is enhanced due to the retention of bounded microbubble to the tumor vasculature and free 
circulating microbubble in the SLN. 
  
Figure 3.1: Averaged pre destruction scan images. It can be seen from the ROI the enhancement 
in the ultrasound signals due to the attached targeted microbubble and free circulating 
microbubbles. This is a scan for a metastatic lymph node.  
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Figure 3.2: Averaged post destruction scan images. It can be seen from the ROI that there is no to 
less enhancement in the ultrasound signals due to the destruction of the microbubbles. This is a 
scan for a metastatic lymph node.  
 
To calculate the mean intensity of the attached microbubble the pre-destruction averaged 
images were subtracted with the post-destruction average image. The resultant image is an RGB 
image which was converted to HSI (Hue-Saturation-Intensity) mode. And the intensity is 
measured and quantified. Similarly the process is repeated on benign nodes and the retention of 
IgG (Control) microbubble was also looked into the metastatic and benign nodes.  Similar steps 
were used to quantify the mean intensity on other nodes as shown in Figure 3.3- 3.8.  
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Figure 3.3: Averaged pre destruction scan images for dual targeted microbubble retention in 
benign node. It can be seen from the ROI that there is no to less enhancement in the ultrasound 
signals due to the benign node.  
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Figure 3.4: Averaged pre destruction scan images for dual targeted microbubble retention in 
benign node. It can be seen from the ROI that there is no to less enhancement in the ultrasound 
signals due to the benign node. 
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Figure 3.5: Averaged pre destruction scan images for IgG (Control) microbubble in metastatic 
node. It can be seen from the ROI that there is no to less enhancement in the ultrasound signals 
since IgG microbubble are not attached in that region. 
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Figure 3.6: Averaged post destruction scan images for IgG (Control) microbubble in 
metastatic node. It can be seen from the ROI that there is no to less enhancement in the 
ultrasound signals since IgG microbubble are not attached in that region.  
 
 
Figure 3.7: Averaged pre destruction scan images for IgG (Control) microbubble 
retention in a benign node. It can be seen from the ROI that there is no to less 
enhancement in the ultrasound signals.  
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Figure 3.8: Averaged post destruction scan images for IgG control microbubble in benign 
node. It can be seen from the ROI that there is no to less enhancement in the ultrasound 
signals. 
 
 
 
 
 
 
3.1.7 Histopathology  
  Tumors were surgically resected after the experiments and were embedded in paraffin 
blocks, which were sectioned (5µm) and stained with hematoxylin and eosin. This was done to 
detect or rule out the presence of metastatic involvement. The detection of the Tumor cells in the 
LN sections was performed according to the established cytological characteristics of melanoma 
cells. [55] Metastatic involvement in the LNs were read and rated (1-100%) by an experienced 
dermatopathologist and the interpretations were used as the reference standard for the 
characterization of benign or malignant LN’s. Once the metastatic involvement was known the 
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slides were divided into 3 sets of 5 metastatic and 5 benign nodes each and were exposed with 
either dual targeted microbubbles, IgG (control) or a set of 12 slides where used for antigen 
retrieval to check for the specific binding of the microbubble in the nodes [58]. Figure 3.9 is a 
flow diagram showing quantification of microbubbles and data processing developed for this 
study to image and quantify microbubble attachment on three type of slides. 
Figure 3.9 Flow diagram showing the steps involved in quantification of image and data processing. 
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3.1.8 Ex-Vivo Bubble attachment study 
To test the ex-vivo binding specificity three sets of 5 metastatic and 5 benign nodes 
where sectioned on a 5.0 µm onto a glass slide. Total number of slides being 144. These slides 
were from six Sinclair swines with naturally occurring melanoma used for this study. The 
sectioning was done in pathology department (Thomas Jefferson University Hospital) and was 
done to check the specific binding for dual targeted, IgG (Control) on the tissues [57-56]. 
Furthermore, to check the microbubble specificity one set of 12 slides were antigen blocked. 
Each set of slides were either exposed in one of the two solution of dual targeted microbubble or 
IgG (Control) microbubble solution. To remove any free floating or unbounded microbubbles 
each set of slide was dipped in PBS solution [57-59]. Subsequently, the slides were dried and 
images were taken using a microscope (Nikon, Labophot-2, and 40x magnification) in phase 
contrast mode and normal mode [59]. Phase contrast mode was used for the imaging of the 
microbubbles and to quantify the attached number of microbubble on the metastatic and benign 
tissue, which were compared to check for differences in microbubble attachment.      
To test the specific binding of the microbubbles to the metastatic SLN’s dual targeted 
microbubble solution was prepared by using 0.5 ml of P-selectin and αVβ3-integrin antibodies 
added to 50 ml of sterile solution within a conical centrifuge tube. In a separate experiment 0.5 
ml of IgG microbubble were prepared by adding to 50 ml of sterile solution within a conical 
centrifuge tube. The slides were removed from storage solution and allowed to air dry without 
making direct contact with the tissue for 2-3 minutes. The slides were dipped either in dual 
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targeted microbubble solution or the IgG solution and gently swirled for 3 minutes. This step was 
followed by gently dipping the slide in 50 ml of stirred PBS, so as to remove any unattached 
microbubble on the slides. Slides were allowed to dry and were mounted with a cover slip. 
For the antigen retrieval and specific bubble attachment the paraffin blocks were 
deparaffinized and 5.0µm section slides were heated in 10 mM sodium citrate buffer (pH 6.0) at 
98o C for 20 minutes in 3, 3′-diaminobenzidine chromogen (DAKO PTLink) [59]. For the 
antigen blocking a 10 ml saline solution was prepared with 50 μl of unbiotylinated P-selectin and 
αVβ3-integrin antibodies. On each slide to be blocked 1 ml of the unbiotylinated solution was 
allowed to sit for 5 minutes and the bubble attachment procedure mentioned above was repeated 
and microscopic images; 4 per slide in phase contrast mode and normal mode were taken. The 
shelf life of the antibodies is 4-5 hours and as a result to save time and to get statically significant 
images for quantification 4 images per slide where taken and quantified to see if there was any 
microbubble attachment or not.   
 The mean number of microbubbles (averaged over per µm) attached on to a slide were 
imaged using a microscope (Nikon, Labophot-2) and the quantification was done by the 
subroutines created on ImagePro-Plus. Microbubbles could be seen as small, rounded structures.  
 To validate the microbubble dimension two criteria were tested and selected; diameter of 
the microbubble and the roundness. A test run was performed to measure the diameter and 
roundness of the microbubble. The range was set keeping the theoretical range of the 
microbubbles along with scanning those microbubbles without the tissue. The diameter range 
was set for microbubble to be from 2.75 µm to 8.00 µm. For this range the minimum roundness 
was measured for the microbubble. The minimum roundness was found out to be 1.65. To test 
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for the upper limit of the range of microbubble roundness, microbubble diameter was tested for a 
range above 8.00 µm. The minimum range for this was found to be 5.02. And as a result the 
criteria for the microbubble selection was determined.  Once this was taken into account three 
subroutines were created in ImagePro plus which are shown in Figure 4.9. The logical behind it 
was as follows; three sub-routines; 1) for light background, 2) malignant background and 3) 
antigen-retrieval were written in ImagePro Plus to quantify the number of microbubbles attached 
to the slide surface listed in Appendix section. Once the sub-routine was run on the slide it gave 
the count of the objects. The range defined above was used to filter un-wanted objects and to 
quantify the microbubbles. The image from the microscope were taken in two modes, phase 
contrast mode and normal mode. Phase contrast mode was used as in phase contrast mode the 
background light is shifted -90° relative to the scattered light; eliminating the phase difference 
between the background and the scattered light, leading to an increased intensity between 
foreground and background making the microbubble determination easier in slides having high 
(more than 65%) metastatic involvement. This method helped in the quantification of 
microbubble which was otherwise difficult to quantify in slides which had 65% and more 
metastatic involvement. Another cause of error was that there were other cellular structures and 
nuclei’s in the diameter and roundness range selected for the microbubble, causing quantification 
problems in the count of the attached microbubbles. 
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284 µm 
Figure 3.10:  Phase contrast mode to measure the microbubbles in a slide without any tissue. This is done so as to 
get a range of value for the microbubble diameter and the roundness 
Microbubbles were studied under a microscope for their quantification criteria. To 
determine their criteria for quantification the measurement in the size of the microbubble was 
taken for the figure 3.10 and a range was set for diameter in µm and the roundness. The diameter 
was selected to be from 2.75 µm to 8.00 µm. This range was set keeping the actual range of the 
Targestar microbubble. For the quantification of microbubble with a tissue there were some 
structure’s having a perfect roundness which had to be kept out of the range so as to differentiate 
between cell nuclei in that range. In other words there was not a significant way to differentiate 
between a microbubble and the tissues which had metastatic involvement of more than 65%.     
 
 
160 µm 
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3.1.9 Statistical Analysis 
To test the in vivo binding of the targeted ultrasound contrast agent molecular CEUS was 
performed and the retained amount of contrast was quantified, described above using a t-test for 
independent variable. The t-test was performed in SPSS. The amount of retention of targeted and 
control bubbles was compared using t-test on groups; benign and metastatic SLN, which were 
determined by the histological analysis. Image processing and quantification was performed 
using image analysis tool ImageJ (NIH, Bethesda, MD). Molecular video intensity were 
quantified based on the comparison between two set of images; a pre-destruction and a post-
destruction data set. The average video intensity for the pre destruction and the post destruction 
was measured for over a region of interest which consisted of the lymph node. The difference in 
the video intensity between pre-destruction and post-destruction was calculated and the resultant 
image was converted from RGB to HSI, where the intensity component was measured and the 
intensity was quantified. 
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4.0 Results  
 
 Six Sinclair swine with naturally occurring 9 melanoma tumors were used for the 
characterization of SLNs in this study. A reticuloendothelial contrast agent Sonazoid was used to 
identify the drainage of melanoma into the regional basin into the first node called as the SLN. A 
total of 23 LNs were scanned in this study using 2 contrast injections per swine (dual targeted 
and control injection). Thus this study involved the analysis of 144 pathological slides and 30 
second averaged ultrasound scans.  
 
4.1 Bubble attachment study 
 An example of a microbubble criteria slide used for microbubble measurement in the 
study is shown in Figures 4.1 and 4.2. The image of the slide is acquired in two modes 1) Phase 
contrast mode and 2) Normal mode. This is done to better differentiate and quantify the number 
of microbubbles attached to the cell surface. The diameter and roundness range of the 
microbubble was determined using the image shown in Figure 4.1 and Figure 4.2. From the 
pathological slides 3 set of slides having metastatic and benign tissue were selected. In total 5 
metastatic and 5 benign slides were selected and four random image per slide were acquired in 
phase contrast and normal mode for dual targeted, IgG and for antigen retrieval. In total 144 
images are analyzed for microbubble retention and compared. The microbubbles on the slide or 
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cell surface were quantified by using two main variables; diameter and roundness. The range for 
the microbubble diameter was selected to be from 2.75 μm to 8.00 μm and roundness from 1.65 
μm to 5.02 μm. An example of a slide used to measure microbubble is shown in Figure 4.1 and 
Figure 4.2 respectively.  This was used as a test to determine the microbubble differentiation 
criteria for images which had tissue in them with metastatic involvement. 
 
 
284 µm 
Figure 4.1 Phase contrast mode to measure the microbubbles in a slide without any tissue in the 
background. This is done so as to get a range of value for the microbubble diameter and the roundness  
 
 
 
160 µm 
47 
 
 
 
284 µm 
Figure 4.2 Normal image to measure the microbubbles criteria i.e. diameter and roundness in a slide 
without any tissue in the background. This is done so as to get an estimate value of the range of 
microbubble diameter and the roundness  
  
 
 
 
160 µm 
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Figure 4.3: A sub-routine was ran to measure the count of an image having microbubbles and no tissue in 
the background taken in a 40x magnification. The image is in phase contrast mode 
  
 
 Figure 4.3 shows an image with microbubbles with no tissue. The image was taken in 
phase contrast mode with a 40x magnification. This image was used to determine the 
microbubble criteria i.e. diameter and roundness. It is known that the diameter value of 
Targestar-SA is from 2µm to 8.00 µm. This was used to determine the diameter and roundness 
range of the microbubble, which was used for the quantification of attached microbubble on the 
melanoma tissue.  
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284 µm 
   
Figure 4.4 Phase contrast image of a metastatic slide having involvement of 20% was analyzed for the 
quantification of the number of microbubbles attached to the cell. The arrow shows the microbubbles 
that were identified on the image.   
 
 
 
 
284 µm 
160 µm 
160 µm 
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Figure 4.5 Normal image of a metastatic slide having involvement of 20% was analyzed for the 
quantification of the number of microbubbles attached to the cell. The arrow shows the microbubbles 
that were identified on the image.   
 
 
The metastatic involvement range for the slides used in this study was from 20% and 
above. Figure 4.4 and 4.5 shows the slide in two different mode where the metastatic 
involvement is 20%. In such slides microbubble count was visualized as shown. However in 
slides which had metastatic involvement of or greater than 60% had a dark background. Due to 
the presence of the dark background in the slides it was difficult to accurately differentiate the 
amount of microbubbles attached to the melanoma tissue. Because of this reason phase contrast 
was used to capture the images and the contrast was inverted in slides having high metastatic 
involvement and microbubble to create a deterministic window for the quantification, it was 
performed as shown in Figures 4.6 and 4.7.  
 
 
284 µm 
160 µm 
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Figure 4.6 Phase contrast melanoma image having metastatic involvement of 80%. For quantification of 
the   number of microbubbles attached in this slide on to the cell the contrast is inverted and microbubble 
quantification is performed.  
 
 
 
 
 
 
 
 
284 µm 
Figure 4.7 Contrast is inverted for the slide which had metastatic involvement of 80%. For 
quantification color thresholding is done so as to accurately count the number of microbubbles attached 
to the melanoma tissue. 
 
Phase contrast imaging and subsequent inversion of contrast on the image might provide 
with the differentiation of microbubble and help in quantification.  However there are some 
overlap in the ranges, meaning there are some cellular structures in the range of diameter and 
roundness that are quantified as microbubbles. Another example of a malignant SLN tissue slide 
is shown in Figure 4.8, while Figure 4.9 demonstrates the contrast inversed image depicting the 
count of microbubbles object in the image. 
160 µm 
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284 µm 
 
Figure 4.8: Shows an image (40x magnification) taken in Phase contrast mode of a melanoma tissue 
having a metastatic involvement of 60%. Because of its dark metastatic background attached microbubble 
count is difficult.  
 
 
 
160 µm 
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Figure 4.9: For quantification the contrast in the malignant slide is reversed and the microbubble are 
quantified. Green color depicts the number of object having microbubble classification criteria; diameter 
and roundness. On the basis of these parameters microbubbles are counted  
 
Figure 4.9 depicts the number of objects that are quantified on the basis of roundness and 
diameter. Range for diameter (2.75μm to 8.00μm) and roundness (1.65to 5.02) was selected to 
get a count for the microbubbles attached on the cell. This data was exported to SPSS (IBM 
SPSS statistics 23) and mean count for the desired range for diameter and roundness obtained for 
each image.   
 
   The average count of microbubble attached within metastatic and normal nodes were acquired 
for comparison between dual targeted, IgG and antigen retrieval in two different charts. One is 
for phase contrast mode and the other for the normal mode. 
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The mean number of microbubble attachment was measured for metastatic node vs normal node 
for dual targeted, IgG (control) and for antigen retrieval. The mean microbubble attachment was 
quantified using two modes: phase contrast mode and normal mode. The comparison in the value 
is shown in Figure 4.10 and Figure 4.11 respectively. Figure 4.10 shows the comparison of 
averaged values of dual targeted and IgG (Control) microbubble retention in phase contrast 
microscopic mode on metastatic tissues, normal tissues and antigen retrieved tissues. Figure 4.11 
shows the comparison of averaged values of dual targeted and IgG (Control) microbubble 
retention in normal microscopic mode on metastatic tissues, normal tissues and antigen retrieved 
tissues.   
 
 
Figure 4.10: Comparison of averaged values of dual targeted and IgG (Control) microbubble 
retention in phase contrast microscopic mode on metastatic tissues, normal tissues and antigen 
retrieved tissues 
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Figure 4.11: Comparison of averaged values of dual targeted and IgG (Control) 
microbubble retention in normal microscopic mode on metastatic tissues, normal tissues 
and antigen retrieved tissues.   
 
 
Figure 4.10 shows the comparison of tissues in phase contrast microscopy mode where 
there are significantly more dual targeted microbubbles attached in metastatic tissues than in 
normal tissues. However, there are more number of IgG (Control) microbubble retention in 
metastatic tissue than dual targeted in normal node. This is a variability of the experiment as in 
theory there shouldn’t be any IgG (Control) microbubble retention this is observed because of 
the small shelf-life of the microbubbles and the difficulty in the differentiation of microbubble 
and the dark metastatic background; leading to up count of cellular structures in the microbubble 
criteria range and as a result showing the variation.  And the overall comparison of microbubble 
retention on metastatic tissue shows significantly more dual targeted microbubbles attached than 
IgG (Control) microbubble, where p=0.001 for phase contrast mode. However, Figure 4.11 
shows the comparison of tissues in normal microscopy mode where there was significantly more 
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IgG (Control) microbubbles attached than dual targeted microbubbles attached in metastatic 
tissues. There is no microbubble attachment on the antigen retrieved slides.       
  The average count for dual targeted contrast agent attachment in phase contrast mode in 
metastatic tissue was higher than IgG (control) (0.06 ± 0.04 vs 0.045±0.03; p=0.001). The 
average count for dual targeted in the normal mode for metastatic was less than that of IgG 
(Control) (0.062±0.04 vs 0.088±0.05; p =0.03) this difference in the value of the microbubble 
attachment is because of the overlap in the transparency range of the microbubble which leads to 
some un-quantified microbubbles. Because of this phase contrast microscopy to quantify 
microbubble attachment is a better method.   
For the antigen retrieval process there was no value generated in the range specified for the 
microbubble diameter and roundness as shown in the Figure 4.10 and Figure 4.11 respectively.  
 
4.2 In vitro data 
 
A total of 11 sentinel and 13 non-sentinel LNs were imaged. Metastatic involvement 
greater than 5% was detected in 7 SLNs, there identification was confirmed by a pathologist at 
Thomas Jefferson university hospital. The mean signal intensity of the dual-targeted contrast 
agent in the metastatic SLNs was significantly higher than in the IgG-targeted control LNs (17.2 
± 15.8 vs 1.5 ± 1.3; p = 0.036). The signal intensity of dual-targeted and IgG-control 
microbubbles in benign LNs was not significantly different (1.5 ± 0.8 vs 1.6 ± 1.6; p = 0.87). 
There was a significant difference in dual-targeted contrast retention in metastatic vs. benign 
LNs (p = 0.04). However, IgG-targeted control contrast agent demonstrated no significant 
retention difference in metastatic vs. benign LNs (p = 0.88). Since the tumor in the swine model 
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can be seen, the tumor measurement was taken prior to the Sonazoid injection. The size of the 
tumor before administration of the contrast agent is shown in Figure 4.12.  
 
 
Figure 4.12: Tumor is scanned before administration of contrast agent. The size of the tumor is measured 
and the ROI is marked. The size of the tumor was 20.1 x 5.4 mm.  
 
 
In order to study the ultrasound data for the bubbles attached and free floating in the 
tumor vasculature the imaging frames were recorded digitally and analyzed offline. A 
commercially available software package ImageJ (NIH, Bethesda, MD) was used for image 
processing and the ROI was manually drawn with the assistance of a radiologist. Two sets of 
cine clips, before and after a high-power destruction sequence were acquired, this is done to 
quantify the adherent microbubble to the tumor vasculature. The average video intensity is 
divided into samples of pre- destruction and post-destruction, which was measured as a relative 
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measure of contrast retention in the LNs. For the analysis of the images, mean intensity of the 
pre-destruction scans were subtracted from the post destruction images. Comparison was done 
for malignant to benign SLN’s for double targeted which was metastatic SLNs and similarly the 
same procedure was used for IgG targeted control. 
 
Figure 4.13: Reproduced from: Molecular Imaging: Imaging tumor angiogenesis with targeted 
microbubbles [58] 
 
The amount of retention of microbubble is measured by calculating the difference in the 
mean number of microbubbles attached in a pre-destruction sequence frames to that of post-
destruction sequence. Figure 4.13 shows that after a bolus injection of dual targeted contrast 
agent is administered in a swine a delay time of 4 minute is allowed so that there is enough time 
for the microbubbles to get attached to the tumor sites. Once attached the SLNs are scanned and 
the scans show the enhanced contrast signals due to attached and free circulating dual targeted 
microbubbles. Once the pre-destruction scans are saved a high mechanical index (MI >0.5) pulse 
is used to destroy the microbubbles in the SLNs. After the destruction pulse post destruction 
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scans are saved for up to 9seconds. Post-destruction pulse there are only free circulating 
microbubbles in the SLNs. To quantify the number of dual targeted microbubble attached the 
pre-destruction set is subtracted from the post destruction. The resultant is the amount of retained 
microbubbles in the SLNs. The resultant image generated is in RGB which is converted into 
HSI, where the intensity is used to quantify the results.   
Figure 4.14 shows averaged images of videos having a time frame of (3 seconds) a total 
of 100 images before destruction pulse were averaged and the resultant image was generated. 
The ROI shows the area which has attached and free floating microbubble concentration. This is 
shown in CPS mode and gray-scale mode. The ROI is selected and the averaged pre destruction 
pulse image is subtracted from the averaged post destruction pulse image shown in figure 4.15, 
the resultant image is generated which consists of the microbubble attached in a sentinel lymph 
node as  shown in Figure 4.16. ROI is selected from the resultant image and the mean intensity 
of the microbubble attached was quantified.  
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Figure 4.14: Averaged images of a Pre-destruction sequence when dual targeted injection is 
administered in the swine. ROI is marked so as to show the microbubble concentration in the ultrasound 
scan in CPS mode and gray scale mode.  
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Figure 4.15: Averaged images of a Post-destruction sequence when dual targeted injection was 
administered in the swine. ROI is marked so as to show the microbubble concentration in the 
ultrasound scan in CPS mode and gray scale mode. 
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Figure 4.16: Resultant image depicting the targeted microbubble retention in a lymph node. The 
microbubble retention suggests metastatic involvement in the node.  ROI is marked in order to quantify the 
mean intensity of the microbubble retention. The final resultant image was generated in HSI (Hue-
Saturation-Intensity) mode, however for quantification the resultant image was converted and quantified for 
intensity of the microbubble attached in the ROI  
 
 
 Figure 4.16 shows the resultant image generated when the averaged pre-destruction 
image was subtracted with the averaged post-destruction images for a dual targeted injection. 
The ROI in the resultant image shows the mean intensity of the targeted microbubbles attached 
to the sentinel lymph node indicating the node to have metastatic involvement in it. The mean 
intensity was measured by quantifying the mean number of targeted microbubble attached in the 
resultant ROI.  
 
Similarly, to quantify and see the microbubble retention in a normal node dual targeted 
injection is administered in the swine and the process is repeated and ROI depicting lymph node 
is shown in the figures 4.17, figure 4.18. 
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Figure 4.17 Averaged images of a Pre-destruction sequence when dual targeted injection is administered in the 
swine. ROI is marked so as to show the microbubble concentration in the ultrasound scan in CPS mode and gray 
scale mode.  
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Figure 4.18 Averaged image of a Post-destruction sequence when dual targeted injection is administered in the 
swine. ROI is marked so as to show the microbubble concentration in the ultrasound scan in CPS mode and 
gray scale mode 
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Figure 4.19 Resultant image depicting no targeted microbubble retention in a lymph node. The 
microbubble retention suggests that this node is a benign node. ROI is marked in order to quantify the mean 
intensity of the microbubble retention if any. The final resultant image was generated in HSI (Hue-
Saturation-Intensity) mode, however for quantification the resultant image was converted and quantified for 
intensity of the microbubble attached in the ROI  
 
Figure 4.19 shows the resultant image generated when the averaged pre-destruction 
image was subtracted with the averaged post-destruction images for a dual targeted injection. 
The ROI in the resultant image shows negligible intensity of the targeted microbubbles in the 
lymph node indicating that the node is benign. The mean intensity was measured by quantifying 
the mean number of targeted microbubble attached in the ROI. 
Comparison between the average final intensity of dual targeted bubbles and IgG microbubbles 
(control) in metastatic SLNs is depicted in Figure 4.20. Figure 4.21 depicts the comparison in 
dual targeted and IgG (control) microbubble retention in a benign lymph node. It can be seen that 
there is no significant retention of dual targeted microbubble and IgG (control) injection in the 
benign lymph node. The difference in the average final intensity of a pre destruction image to a 
66 
 
post destruction image represents the average intensity of microbubbles attached to a metastatic 
lymph node. 
 
 
Figure 4.20: Depicts the comparison in dual targeted and IgG (control) microbubble retention in a metastatic lymph 
node. It can be seen that the dual targeted microbubble retention is significant high in metastatic node for dual 
targeted injection when compared to IgG Control injection. 
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Figure 4.21: Depicts the comparison in dual targeted and IgG (control) microbubble retention in a benign lymph 
node. It can be seen that there is no significant retention of dual targeted microbubble and IgG (control) injection in 
the benign lymph node.  
 
 
Figure 4.22 shows the comparison in the retention of dual targeted microbubble in metastatic 
node and benign nodes. It can be concluded that the dual targeted microbubble retention in the 
metastatic node is significantly higher than in the benign node. Figure 4.23 shows the 
comparison in the retention of IgG (control) microbubbles in metastatic lymph nodes and benign 
lymph nodes. It can be inferred that there was no significant IgG microbubble retention in 
metastatic and benign lymph nodes.   The comparison for metastatic and benign nodes for dual 
targeted microbubbles is depicted in Figure 4.22, while the difference in the metastatic node and 
the benign node for IgG (control) bubbles is shown in Figure 4.23. 
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Figure 4.22: Depicts the comparison of mean intensity for dual targeted injection in metastatic node vs benign 
nodes. 
 
 
 
Figure 4.23: Difference in the mean intensity for IgG (Control) injection in metastatic and benign node. 
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significantly different (1.5 ± 0.8 vs 1.6 ± 1.6; p = 0.87). There was a significant difference in 
dual-targeted contrast retention in metastatic vs. benign LNs (p = 0.04). However, IgG (control) 
contrast agent demonstrated no significant retention difference in metastatic vs. benign LNs (p = 
0.88). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
70 
 
 
5.0 Discussion  
 
   
 There was a significant difference obtained in the in-vivo study for the comparison of 
mean intensity signal in dual targeted microbubble attachment to IgG (control) in a metastatic 
sentinel lymph node (r = 0.429, p=0.036) was higher. The difference was not significant when 
the signal intensity was compared for dual-targeted and IgG-control microbubbles in benign LNs 
(1.5 ± 0.8 vs 1.6 ± 1.6; p = 0.87). Furthermore, IgG (control) contrast agent showed no 
significant retention of microbubble in metastatic vs benign lymph nodes (p=0.88). This data was 
supported by the in vitro data where the average microbubble attached count for dual targeted 
contrast agent in phase contrast mode in metastatic tissue was higher than IgG (control) (0.06 ± 
0.04 vs 0.045±0.03; p=0.001). The average count for dual targeted vs IgG (Control) in normal 
mode microscopy for metastatic node was (0.062±0.04 vs 0.088±0.05; p=0.03). The in-vitro data 
findings suggested that there was a significant difference in the number of dual targeted 
microbubbles attached in metastatic tissues than IgG (Control) when the images where taken in 
phase contrast mode with a magnification of 40x (p=0.001). However, when the results were 
compared for normal mode microscope images the results suggested that there were more 
number of IgG (Control) microbubbles attached in metastatic mode than dual targeted 
microbubbles (p=0.03). There are number of limitations for the in-vitro binding of dual targeted 
microbubble attachment on the tissue. Firstly, the slides which had metastatic involvement more 
than 65 % had dark background, it was difficult to differentiate between the background and the 
microbubble. Phase contrast method was used to overcome this limitation however, it was really 
difficult to differentiate the dark background for the slides which had metastatic involvement 
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more than 80%. It generated a smaller window for the attached microbubble count causing a 
population of attached microbubbles not being quantified. To overcome the limitations in the 
quantification of the microbubble, microbubble criteria was defined with a range of diameter and 
roundness. However, even after defining this range there were intracellular matter that fell in this 
range and were quantified as microbubble, which were in reality objects other than the 
microbubbles. Another aspect that was not considered was if there were accumulation of more 
than one microbubbles forming a cluster and not falling in the range of the diameter and 
roundness defined; where not counted in the count for the quantification of the microbubble 
attached. Additionally, the slides that were used for the bubble attachment study were from six 
different swine’s having metastatic and benign nodes being sectioned and placed on the slides for 
analysis. If there was an up count there should be for both the dual targeted and IgG (Control) 
microbubbles, but since the sections were cut in planar slices which might have a variation in the 
number of cellular structures in the tissues for the range defined for the microbubble 
quantification because of which the count for the attachment of the IgG (control) in normal mode 
was greater than dual targeted attachment for the metastatic tissues.     
 Several studies have been conducted where contrast enhanced ultrasound with 
microbubbles was targeted to specific growth factors expressed on neovascular endothelium to 
image tumor angiogenesis. For example a study conducted by Lindner et al. in 14 athymic rats 
which were used to produce malignant gliomas. In this study CEU was performed with 
microbubbles targeted to αvβ3– integrin which is expressed on the tumor neovascular 
endothelium. They were able to show the increase in CEU signal over a period from 14 to 28 
days (1.7±0.4 versus 3.3±1.0 relative units, P<0.05) [56]. This study significantly showed the use 
of targeted microbubbles in CEUS to noninvasively detect early tumor angiogenesis [56].  An 
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accurate detection and characterization of sentinel lymph nodes (SLN) that receive the drainage 
from a primary cancer is an important prognostic factor in predicting survival. One such study by 
Forsberg et al, 2005 looked into the detection of lymphatic channels and sentinel lymph nodes 
with and without metastases can be determined with lymphatic ultrasonography. They used an 
US contrast agent to determine and assess SLN’s for the presence of metastatic infiltration. In 
that study they had determined 28 SLN’s which were compared with dissection of the lymph 
node after a blue dye was injected in the swine. They concluded a 90% accuracy in detection of 
SLN’s using lymphatic ultrasound. And correctly determined metastasis in 19 out of 20 SLNs 
and 5 out of 8 correct normal SLN’s characterization was performed with an accuracy of 86% 
[57]. This study concluded that correct and accurate detection of metastatic SNL’s can be 
performed using contrast enhanced ultrasound.  
 One of the new and promising imaging modalities that can be potentially used for 
metastatic lymph node characterization is molecular ultrasound (Lyshchik 2007). Molecular 
ultrasound contrast agents are microbubbles targeted to specific molecular markers by adding 
high-affinity ligands onto the surface of the contrast agent. Following intravenous administration 
these targeted ultrasound contrast agents accumulate at tissue sites overexpressing specific 
molecular markers thereby enhancing the ultrasound imaging signal. One such study deals with 
the relationship between the retention of vascular endothelial growth factor receptor 2 (VEGFR-
2) targeted ultra-sonographic contrast agent and level of VEGFR2 expression. In this study they 
were able to show a significant retention in the number of VEGFR-2 targeted microbubbles 
which was higher than retention of non-targeted microbubbles (mean ± SD, 47.75 ± 9.85 versus 
18.5 ± 5.46 dB; P< .001). They were also able to show a correlation between the retention of 
VEGFR-2 targeted contrast agent to the level of VEGFR-2 expression in the tumor under study 
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(r2 = 0.41). They concluded with this study that molecular imaging can be used for in-vivo 
detection and expression in a breast cancer model, furthermore the magnitude of the molecular 
ultrasound signal from the retained targeted VEGFR-2 ultrasound contrast agent correlated with 
the amount of VEGFR-2 expression in the cancer [58].      
 As it was shown by Lyshchik et al 2007 that molecular ultrasound is an effective tool in 
detecting tumor angiogenesis and can be used for characterization of metastatic lymph node non-
invasively. The results obtained in this thesis project shows that molecular ultrasound can 
characterize and identify metastatic lymph nodes and non-SLN’s in the melanoma swine model. 
To accomplish this goal Sonazoid was administered sub-dermally to detect the sentinel lymph 
node. After the SLN are identified dual targeted injection is administered, this study is the first 
time a dual targeted injection is administered in a Sinclair swine to check for neoangiogenesis 
within the metastatic lymph node. The use of conventional lymphosonography along with 
molecular ultrasound has allowed precise characterization of the metastatic lymph nodes in 
naturally occurring melanoma model.  
 The in-vitro data showed the high significant difference in retention of dual targeted 
microbubble in metastatic tissue than less number of quantified IgG (Control) microbubble in 
benign tissues. These microbubbles where compared in two microscopic mode; phase contrast 
and normal mode to compare the difference in the number of dual targeted microbubble attached 
to a metastatic tissue vs benign tissue and IgG(control) microbubble attachment to metastatic vs 
benign tissue. The results showed that the dual targeted microbubble retention in phase contrast 
mode was significantly higher in metastatic tissues over benign tissues. And there wasn’t any 
significant difference in IgG (control) microbubble retention in metastatic to benign tissues. To 
further test the binding of the dual targeted microbubble to metastatic tissues; antigen retrieval 
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was performed on metastatic tissues and benign tissues. The results showed no dual targeted 
microbubble attachment on the antigen retrieved slides, similarly no IgG (control) microbubble 
attachment was found on the antigen retrieved slides.   
Furthermore, the in-vivo data also supports the in-vitro data suggesting that there was a 
significantly high mean intensity signal in nodes which were metastatic to those which where 
benign, suggesting the dual targeted microbubble retention in metastatic lymph nodes. 
Additionally, the IgG (Control) microbubble retention was not significant suggesting that the 
ultrasound signals were not enhanced in the metastatic and benign depicting less to no 
attachment of microbubble. The results of the ultrasound scan were stored offline and compared 
to suggest a high significant difference in the dual targeted microbubble retention in metastatic 
lymph nodes to benign lymph nodes.       
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6.0 Conclusion and future work 
 
 The overall objective of the study was to characterize the metastatic involvement in LNs 
using molecular imaging with dual targeted microbubbles in a swine animal model. For this 
study two molecular markers of angiogenesis, which are overexpressed during angiogenesis, 
were considered. 
 Two molecular biomarkers of angiogenesis were considered for the study: P-selectin and 
αVβ3-integrin. To characterize the sentinel lymph node dual targeted microbubble was used. The 
dual targeted microbubble attach to the biomarkers which are overexpressed at the tumor 
vasculature during tumor angiogenesis.  It was shown in this study that there was a significant 
difference in the average intensity of dual targeted microbubbles attached to metastatic node 
when compared with IgG (Control) microbubbles. This satisfies the objective of the study to 
identify the metastatic SLN in swine model using molecular imaging. Furthermore, there was a 
significant difference in the phase contrast in-vitro binding affinity for dual targeted microbubble 
on metastatic lymph nodes when compared with IgG (Control) microbubble. However, due to 
the variations in the in-vitro data there were inconsistencies showing that there were more IgG 
(Control) attached in the metastatic nodes than dual targeted nodes. This was the unexpected 
result since in theory IgG (Control) bubbles don’t attach to the metastatic nodes. This was 
observed and proved in the in-vivo studies where the average intensity of attached dual targeted 
microbubble was significantly greater than the IgG (Control) contrast agent in metastatic lymph 
nodes.    
The results presented in this study are based on a limited sample size (6 swines). A study 
with more number of swine would increase the statistical power of the study. Another problem of 
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concern in this study was that in some slides which had 65% and more metastatic involvement in 
them it was difficult to quantify microbubbles. Additionally, there were structures whose 
dimensions overlapped with that of the microbubble. Because of this reason there variation in the 
in-vitro study for the bubble attachment. If there is any method that can show the difference 
between the overlap that would significantly help in microbubble quantification.  
We saw a difference in the mean intensity of accumulation of dual targeted contrast agent 
in the metastatic nodes relative to benign nodes with contrast ultrasound scans. Similarly, there 
was no difference in the mean intensity of microbubble attachment for control injections 
performed in metastatic compared to benign nodes. These results were consistent with the 
microbubble attachment study which showed that there is a significant difference in the mean 
number of microbubble that are attached to metastatic node vs benign node for dual targeted 
performed in the phase contrast mode.  
Since angiogenesis plays a major role in the growth of tumor neo-vasculature and 
promote metastases, and it is imperative to conduct research on early detection of tumor 
angiogenesis. The potential long term benefit of this study would be in development of a 
minimally invasive imaging methodology to identify and differentiate between SLN with 
metastatic involvement and SLNs without using targeted contrast agents in patients with 
melanoma. Additionally, this method can be used in other cancers which have similarly 
lymphatic drainage. This method can be used to differentiate metastatic and non-metastatic 
lymph nodes, subsequently decreasing the need to perform excisional lymph node biopsies. Due 
to the ability to characterize metastatic SLNs and non-metastatic SLNs dual targeted CEUS and 
can be used to significantly reduce the need to perform radical lymph node resection by detecting 
the SLNs non-invasively. 
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Appendix A: List of Statistical tests used  
 
 
 Independent Sample t-test (Paired and unpaired) 
o Paired t-test  
 Independent sample t-test was used to find significant difference in the mean intensity of 
dual targeted injection and IgG (Control) injection and these microbubble retention on the 
malignant nodes. Similarly the difference not significant was measured for dual targeted 
microbubble vs IgG(Control) for benign nodes 
 
o Unpaired t-test  
Unpaired t- test was done to show significant difference in the attachment of dual 
targeted microbubbles in metastatic nodes to IgG (Control) microbubbles in metastatic 
node. Similarly, to check the difference in the attachment of dual targeted vs IgG 
(Control) in benign node unpaired t-test was performed  
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Appendix B: List of Subroutines 
 To quantify the number of microbubble attached in the malignant tissues the following 
subroutine was created. 
Sub Malignant_Count_New_() 
 ret = IpSCalSelect("circuit x5000") 
 ret = IpSCalShowEx(SCAL_DLG_SELECT, SCAL_HIDE) 
 ret = IpLutSetAttr(LUT_CONTRAST, -1) 
 ret = IpBlbShow(1) 
 ret = IpBlbSetAttr(BLOB_AUTORANGE, 0) 
 ret = IpSegShow(1) 
 ret = IpSegShow(2) 
 ret = IpSegSetAttr(SETCURSEL, 0) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegShow(1) 
 ret = IpSegShow(2) 
 ret = IpSegSetAttr(SETCURSEL, 0) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegShow(1) 
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 ret = IpSegShow(2) 
 ret = IpSegSetAttr(SETCURSEL, 0) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegShow(1) 
 ret = IpSegSetRange(0, 0, 23901) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegShow(2) 
 ret = IpSegSetAttr(SETCURSEL, 0) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegSelectArea (SEG_SELADD, 4, 964, 1264, 7) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegShow(0) 
 ret = IpBlbCount() 
 ret = IpBlbUpdate(0) 
 ret = IpBlbEnableMeas(BLBM_MINFERRET, 0) 
 ret = IpBlbEnableMeas(BLBM_MAXFERRET, 1) 
 ret = IpBlbMeasure() 
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 ret = IpBlbCount() 
 ret = IpBlbUpdate(0) 
 ret = IpBlbShowData(1) 
End Sub 
 To count the number of microbubble if any in no to 50% metastatic involvement the 
following subroutine was created and used for the qunatiifcation of the microbubble 
NEW_COUNT_1() 
 ret = IpHstEqualize(EQ_BESTFIT) 
 ret = IpSCalSelect("circuit x5000") 
 ret = IpSCalShowEx(SCAL_DLG_SELECT, SCAL_HIDE) 
 ret = IpBlbShow(1) 
 ret = IpSegShow(1) 
 ret = IpSegShow(2) 
 ret = IpSegSetAttr(SETCURSEL, 0) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegShow(1) 
 ret = IpSegShow(2) 
 ret = IpSegSetAttr(SETCURSEL, 0) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegShow(1) 
 ret = IpSegSetRange(0, 10496, 13878) 
 ret = IpSegPreview(ALL_C_T) 
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 ret = IpSegSetRange(0, 10496, 13878) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegSetRange(0, 11776, 13878) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegSetRange(0, 11776, 20022) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegSetRange(0, 11776, 18230) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegSetRange(0, 11776, 18230) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegSetRange(0, 11776, 19571) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegSetRange(0, 11775, 19571) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegSetRange(0, 17152, 19571) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegShow(0) 
 ret = IpBlbCount() 
 ret = IpBlbUpdate(0) 
 ret = IpBlbShowData(1) 
End Sub 
 
90 
 
 To see any attachment of microbubble in anti- retrieval process the subroutine used to 
quantify the microbubbles is as follows:  
aNTIGEN_RETRIEVAL_() 
 ' New workspace document ID is 0 
 ret = IpBlbShow(1) 
 ret = IpSegShow(1) 
 ret = IpSegShow(2) 
 ret = IpSegSetAttr(SETCURSEL, 0) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegShow(1) 
 ret = IpSegShow(2) 
 ret = IpSegSetAttr(SETCURSEL, 0) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegShow(1) 
 ret = IpSegSetRange(0, 15872, 29041) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegSetRange(0, 15872, 21105) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegSetRange(0, 18432, 21105) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegSetRange(0, 18432, 19569) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegSetRange(0, 18432, 18545) 
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 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegSetRange(0, 18432, 21873) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegSetRange(0, 12544, 21873) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegSetRange(0, 12544, 17265) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegSetRange(0, 12544, 15217) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegSetRange(0, 12544, 14193) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegSetRange(0, 12544, 14961) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegSetRange(0, 10496, 14961) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegSetRange(0, 10496, 11121) 
 ret = IpSegPreview(ALL_C_T) 
 ret = IpSegShow(0) 
 ret = IpBlbCount() 
 ret = IpBlbUpdate(0) 
 ret = IpBlbShowData(1) 
End Sub 
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Appendix C: List of software used 
  
1. ImageProPlus 7.0 (Media Cybernetics) 
Purpose: To perform in-vitro bubble attachment studies in phase contrast and normal 
mode to quantify number of microbubbles attached 
License: Thomas Jefferson University Hospital 
 
2. SPSS (IBM SPSS Statistics  
Purpose: To perform t-test  
License: Drexel University 
3)   ImageJ (NIH, Bethesda, MD) 
Purpose: To provide averaging of ultrasound data and to calculate the amount of   
microbubbles attached in a node by user marked ROI’s 
4) Microsoft Office 2013 (Microsoft Corporation, Redmond, VA) 
      Purpose: For publishing, data handling and presentation  
      License: Drexel University  
 
  
